Shield Therapeutics PLC: Hitting its clinical targets
Shield Therapeutics (LON:STX) has reported further data from its non-inferiority AEGIS H2H study of oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) versus intravenous ferric carboxymaltose (IV FCM), which is the standard second-line treatment for iron deficiency anaemia (IDA). The data from the multi-national Phase 3b randomised trial in inflammatory bowel disease (IBD) patients with IDA, supported the headline data reported in March, providing additional material to support commercialisation and reimbursement efforts in a global iron replacement market worth circa US$3bn.
The data, which were presented at the 27th United European Gastroenterology Week (UEG) by Dr Stefanie Howaldt, principal investigator of the AEGIS trial, included additional detail on the longer-term data out to 52 weeks and confirmed not only that the primary endpoints were met, but that Feraccru prevented the recurrence of IDA, providing a real oral alternative to IV iron. These outcomes provide strong support for the positioning of STX’s oral treatment for current and potential partners including in a broad preventative setting.
Quick facts: Shield Therapeutics PLC
Price: 119.95 GBX
Market Cap: £140.57 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE